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Kidney transplantation is inevitably faced with overcoming the immune response to the 
grafted organ, necessitating immunosuppressive therapy. Further, the immunogenicity of 
the graft is augmented by the initial ischemia-reperfusion injury, which negatively 
influences both acute and chronic renal graft failure. Because of its systemic nature, current 
immune suppression is a trade-off of efficacy against side-effects. Local, rather than 
generalized, immunosuppression or tolerogenic strategies may improve graft survival and 
quality of life of the transplanted patients. Targeted (over)expression of molecules that are 
able to modulate the immune reaction locally, in the graft, offers a strategy to shield the 
transplanted kidney against rejection, while leaving the immune system virtually 
unaffected. Gene therapeutic approaches may transform the theory of local immune 
suppression into reality. In addition, gene therapy may be instrumental in expanding the 
donor pool from non-heart beating donors and ameliorate ischemia-reperfusion injury in 
both living-related as well as deceased kidney transplantation. The aim of this study was to 
investigate (1) the potential of gene therapy with Interleukin-13, an immunomodulatory and 
cytoptotective cytokine, to mitigate renal I/R injury and acute kidney transplant rejection 
and (2) the potential of local immunosuppressive gene therapy in kidney transplantation. 
The prerequisites of a successful gene therapy are an efficient, safe and selective vector, 
an appropriate technique and an appropriate gene (reviewed in chapter 2). Using both viral 
and non-viral vectors and employing various techniques, specific cell compartments of the 
kidney can be targeted. However, while plenty of studies show successful reporter gene 
delivery to the kidney, the number of functional studies with gene therapy in models of 
kidney disease in general and in transplantation in particular, is surprisingly low, 
presumably reflecting an insufficient transfection efficiency of the vectors used. From the 
available vectors for gene therapy, adenoviruses offer good perspectives, as they are able to 
infect a wide variety of cells, they have a relative high efficiency, are easy to produce on 
large scale and, important for kidney transplantation, they preserve their infectivity at low 
temperature. As a first step towards successful gene therapy for transplanted kidney, we 
employed in chapter 3 as vector a modified first generation adenovirus, which has an 
additional RGD sequence in the fiber knob1. With this modification, both CAR (coxsackie 
adenovirus receptor)-dependent and CAR-independent (RGD-integrin-dependent) cell 
entry pathways are accessible for adenovirus, thus allowing enhanced infectivity. Indeed, 
the RGD-modification increased approximately 5-fold the transduction efficacy of the 
adenovirus, without enhancing the immune reactivity to viral genes in our model of rat 
kidney transplantation. Importantly, transgene expression was restricted to the renal graft, 
hence allowing selective, local gene therapy. With this vector and using an infusion-
clamping technique, reporter gene (GFP) expression was found almost exclusively in the 
interstitial fibroblasts. As the interstitium of the renal graft is the stage of both immune 
infiltration, as well as long-term fibrosis, the most straightforward applications of fibroblast 
targeting in the context of kidney transplantation are local modulation of the immune 
microenvironment in the interstitium or blockade of fibroblast activation. As previously 
reported with the first generation adenoviruses (see chapter 2), the transgene expression 
was short-lasting (weeks), due to the adaptive immune response elicited by this type of 
adenovirus, making this vector suitable for short-term studies. We therefore aimed at 
investigating the potential of gene therapy in two of the most common acute events 




following kidney transplantation, which are the ischemia-reperfusion (I/R) injury and the 
acute rejection (AR).  
Donor organs inevitably undergo ischemia followed by reperfusion, leading to variable 
degrees of damage (I/R injury). Especially long ischemia, as encountered in non-heart-
beating donor kidneys, is accompanied by severe I/R damage2, with both acute implications, 
i.e. delayed/non-graft functioning and acute rejection, and chronic consequences (chronic 
allograft nephropathy). To prevent or inhibit damage, one should know its cause and 
mechanism. For this purpose and taking advantage of the available microarray technique3, 
we performed in chapter 4 an analysis of renal gene expression at several time points during 
a 3 week period after I/R, in a rat model. Our data confirmed changes in expression of genes 
already identified as being involved in I/R injury, such as transcription factors, stress 
response proteins, inflammation-related products and, at later time points, cell adhesion and 
extracellular matrix molecules. The two most important findings of this study are: (1) there 
is a quick and transient up-regulation of (mainly transcription) factors able to initiate not 
only an acute response to (hypoxic/oxidant) stress, but also a healing process through 
activation of inflammation and pro-fibrotic pathways; (2) factors (such as Egr-3 and Btg-2) 
that link innate and adaptive immunity come to expression after I/R injury, a process that 
was regarded till recently as being exclusively an innate immune response4. In addition, in 
view of the following gene therapy studies, the pattern of several markers of renal I/R 
damage in time was defined: Kidney Injury Molecule (KIM)-1 for tubular damage; ED-1 
(macrophages) for inflammation; α-smooth muscle actin (SMA) and collagen III for early 
and late fibrotic changes, respectively.  
From a pathophysiologic perspective, a proper gene candidate to attenuate I/R injury 
and AR should combine anti-oxidant and anti-apoptotic properties with anti-inflammatory 
and immunomodulatory effects. Such a gene product is Interleukin(IL)-13. Previous data 
coming from studies in liver had documented strong protection from I/R with IL-135;6. As a 
proof of principle, chapter 5 investigates the effects of systemic (i.m.) IL-13 gene therapy in 
the renal I/R model described in chapter 4. Earlier studies showed that injection of 
adenoviruses in limb muscles (i.m.) is a feasible approach to deliver gene products 
systemically7. Indeed, following i.m. injection of an RGD-adenovirus carrying the gene for 
IL-13, systemically circulating IL-13 levels were detectable for approximately 2 weeks. To 
ascertain that therapeutic levels of IL-13 were present at the time of I/R, i.m. delivery was 
performed 2 days prior to the I/R procedure. We demonstrated that IL-13 preserved renal 
histology and function after I/R. Specifically, IL-13 reduced tubulo-interstitial damage both 
on short and long-term (till day 14 after I/R), and limited neutrophil and macrophage 
infiltration by approximately 50% of their values in controls. This was associated with 
down-regulation of E-selectin and TNF-α mRNA levels, and, unexpected, with an almost 
unchanged expression of HO-1, which was described as a putative mediator of IL-13 
protective effects in liver I/R8;9. This apparent discrepancy remains to be clarified; a possible 
explanation is that tubular epithelial cells, which are the major renal source of HO-1 in this 
model, do not express IL-13 receptors. Thus, this study confirmed IL-13 as a novel and 
potent target for preventing renal I/R injury. 
In a further step towards gene therapy for transplanted kidney, and taking advantage 
of the RGD-adenovirus vector described in chapter 3, we studied in chapter 6 the effects of 
local gene therapy with IL-13 on the acute rejection of the renal graft in rats. Systemic 




for comparison with regard to efficiency of the gene therapy approach. We showed that IL-
13 reduced macrophage and CD8+ T cell infiltration, and down-regulated E-selectin, TNF-α 
and IFN-γ mRNA levels. Moreover, we found that expression of α-SMA was inhibited by 
approximately 40% compared to controls. Remarkably, the protection conferred by local as 
compared to systemic IL-13 therapy was similar, though elevated systemic IL-13 plasma 
levels were only found after i.m. gene therapy. One could speculate that the effects we 
found were exclusively locally-mediated. Or that the effects seen in the two treatments are 
(at least partially) the results of IL-13 acting on different (systemic vs. renal) cell types. 
However, the exact mechanisms involved herein remain to be investigated. We concluded 
that application of local IL-13 gene therapy appears as a feasible strategy to suppress the 
immune response locally, in the renal graft, and thereby to protect the graft against acute 
rejection. 
Although the rat model is suitable for studying transplantation-related kidney damage, 
several other small species of mammals may provide new insights into better organ 
protection. Mammalian hibernation has been perceived as a natural model of repetitive I/R 
devoid of damage. As reduced endothelial-derived NO is incriminated as an important 
mediator of early injury during I/R injury10, whereas maintenance of eNOS activity trough, 
for instance, inhibition of Rho kinase11 attenuates I/R injury, we investigated in chapter 7 the 
expression of eNOS in hibernating ground squirrels. The main finding of this study was that 
eNOS expressed by endothelial cells of the peritubular capillaries and arterioles 
(“interstitial” eNOS) was unaffected by the hibernation, whereas glomerular eNOS was 
decreased throughout hibernation. In view of the fact that the tubules are the renal 
structures most sensitive to ischemic damage, and that eNOS-derived NO has vasodilatory 
and protective effects, it can be speculated that hibernating squirrels preserve their eNOS 
expression in the peritubular capillaries as a strategy to protect the tubules against I(/R) 
injury and to allow immediate restoration of tubular function during arousal. Is such a 
strategy applicable to the donor kidneys? Brodsky et al.12 showed that infusion of genetically 
modified cells (over)expressing eNOS into the I/R kidneys protected from I/R injury. 
Alternatively, NOS could be targeted to the endothelial cells through, for instance, an 





Improving the effects of IL-13 on AR through anti-T cell strategies 
One of the most important finding of this thesis was that (over)expression of IL-13 in the 
donor kidney was able to diminish the acute immune response (chapter 6). Still, the effect on 
(CD8) T cell infiltration appeared less pronounced compared to that on macrophages. To 
improve these effects, one obvious approach is to combine IL-13 with a molecule that is able 
to inhibit chemotaxis or/and T cell proliferation or function. Such a molecule is 2,3-
Indoleamine dioxygenase (IDO). IDO is the rate limiting enzyme in the catabolism of 
tryptophan, which is an amino acid essentially required for T cell survival, activation and 
proliferation13. Tryptophan starvation together with the tryptophan metabolites kynurenins 
may promote T cell apoptosis, induce T cell ignorance, anergy or generate regulatory T 
cells13;14. IDO is abundantly expressed in placenta (Figure A) and is crucially involved in 
maternal tolerance15. In addition, many tumors express IDO as a mechanism to escape the 




immune surveillance of the host16. In our rat model of acute kidney transplant rejection, we 
found IDO expression to be limited to a few cells in the inflammatory infiltrates (Figure B). 
In view of this data, it is conceivable that overexpression of IDO in the renal graft using the 
available RGD-adenovirus vector system would protect the graft against rejection. In 
addition to its effects on T cells, IDO has also anti-oxidant properties17 and hence may 
further protect the graft from I/R injury, on top of the already documented effects of IL-13. A 
study regarding the effects of IDO gene therapy on AR of the transplanted kidney is 
ongoing. 
 
Gene therapy for chronic allograft nephropathy 
A major problem still to be solved in organ transplantation is chronic allograft failure. 
Following kidney transplantation, more than 50% of the patients develop progressive renal 
dysfunction, necessitating dialysis or a new graft within 10 years18. As the pathogenesis of 
chronic allograft nephropathy (CAN) involves both immune and non-immune factors (see 
chapter 1), multiple therapeutic strategies have been attempted, none 
of them being yet effective. Can gene therapy take this challenge? 
1. long-term immune suppression or tolerogenic strategies 
A successful therapeutic strategy for CAN needs to interfere with its pathogenesis, to be 
local, long-term and non-toxic. As an alternative to the currently used systemic immune 
suppression, gene therapy offers the possibility of local immune surveillance. We (this 
thesis) and others (see chapter 2) have shown that local immune suppression through gene 
therapy can prevent AR. To combat chronic rejection, long-lasting vectors such as the 
helper-dependent (“gutless”) adenoviruses or adeno-associated viruses offer a good 
perspective. In the “gutless” adenovirus19 the whole coding sequence of the viral genome 
has been removed, making the vector longer-lasting, safer (due to the lack of adaptive 
immune response against the viral genes) and increasing its coding capacity (so that several 
genes that target different pathways can be employed). As RGD-adenovirus is more 
effective in transducing the kidney than the unmodified virus, to optimize the “ gutless” 
adenovirus, insertion of the RGD sequence into the fiber knob would be required. In 
addition, as repetitive immune injury is incriminated in the development of CAN20, 
adjustable instead of continuous immunosuppression would likely be more appropriate. To 
adjust the level of immune suppression in chronic gene therapy, activation of interstitial 
fibroblasts may be used, as they act as “sensors” of local immune activation. Hereto, 
therapeutic genes, such as IL-13 and IDO, may be placed under the control of promoters 
with response elements of signaling routes that are activated in renal fibroblasts by the 
immune response, such as TGF-β or PDGF21.  
Another alternative to continuous systemic immune suppression is induction of 
tolerance (i.e. the lack of a destructive response against the graft in a fully immune 
competent recipient). Drug-free tolerance is rare in human kidney transplantation, as 
interruption of immunosuppression therapy usually leads to AR or chronic rejection22. 
Besides donor bone marrow transplantation23 or infusion of immature donor dendritic cells 
prior to engraftment24, gene therapy with blockers of co-stimulatory pathways of T cell 
activation, such as CTLA4Ig, have shown promising results25. Notably, the tolerogenic 






Figure. IDO expression in human placenta and in acutely rejected rat transplanted kidney. Human 
placenta exibits abundant expression of IDO (arrows) (A), whereas a limited number of IDO positive 
cells (arrows) are seen in acutely rejected rat (B) (immunohistochemistry). 
 
2. anti-fibrotic strategies 
Extensive tubulo-interstitial fibrosis is a hallmark of CAN. Incriminated herein are I/R 
damage, repetitive immune insults, proteinuria, hypertension. Irrespective of the trigger, the  
common pathway is the activation of interstitial fibroblasts (myofibroblasts)27;28. With 
progressive fibrosis, tubular epithelial cells may also acquire a fibroblast-like phenotype 
(epithelial mesenchymal transition), further aggravating the fibrotic process29. Blockade of 
fibroblast activation seems crucial to limit long-term fibrosis. We showed that (both local 
and systemic) IL-13 therapy inhibited early activation of fibroblasts, as documented by 
reduced α-SMA expression, though whether this was a direct effect of IL-13 on the 
interstitial fibroblasts or secondary to inhibition of inflammation needs further investigation. 
This was associated with reduced long-term fibrosis. With the RGD-adenovirus, most of the 
transduced cells were interstitial fibroblasts (see chapter 3). Thus, in addition to the IL-13 
gene therapy, targeted blockade of, for instance, transforming growth factor (TGF)-β 
(through Smad7), or overexpression of anti-fibrotic factors, such as bone morphogenic 
protein (BMP)-7 or hepatocyte growth factor (HGF) via an RGD-“gutless” adenovirus seems 
feasible and may ameliorate long-term tubulo-interstitial fibrosis and thereby CAN. 
  
Clinical perspectives  
Kidney transplantation is nowadays generally viewed as the best therapeutic option for 
patients with end stage renal disease (ESRD). The life expectancy of patients with ESDR 
receiving a cadaveric kidney is twice as long as compared to patients remaining on chronic 
dialysis, even in elderly patients or after a long period of dialysis30. The demand for donor 
kidneys grows along with the number of patients with ESRD31 and with ageing of the 
human population. Notwithstanding the increasing reliance on living donors, the waiting 
lists become longer every year. About 50% of the transplanted patients re-enter the waiting 
lists after 10 years due to CAN32, adding to the already existing shortage of donors. Apart 
from efforts to increase the donor pool, extending the life span of the graft  deserves full 
attention. This thesis shows that gene therapy can contribute to that in two ways: (1) 
optimize the outcome of cadaveric renal transplantation, by protecting the donor organ 
against I/R injury, and (2) improve the graft survival through local rather than systemic 




immune suppression. With the development of more efficient, safer and longer-lasting 
vectors for gene therapy  and with the advances in understanding the molecular pathways 
underlying (chronic) rejection, one expects that in short time we shall arrive at a point where 
clinically suitable vector(s) and gene products will be available. Of course, extensive testing 
in animal models is first needed before making the step to humans. Entering the clinical 
arena with gene therapy always imposes a hurdle, in view of the negative publicity on gene 
therapy brought by few cases of fatal side-effects induced by some of the vectors used33;34. In 
addition, gene therapy with immunomodulatory agents may be considered with even more 
suspicion because of the recent TeGenero case35, implicating that interference with 
mechanisms that control the immune system, such as regulatory T cells, may have dramatic 
side-effects. Finally, surprisingly, out of the about 1200 ongoing clinical gene therapy trials, 
none regards, to our knowledge, kidney transplantation. Consequently, while experimental 
gene therapy in kidney transplantation is advancing rapidly, its image and the lack of 
expertise in human trials may impede its entrance into the clinic. To prevent any delay, we 
better start preparing for clinical testing today. Not only for the benefit of the individual 
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